Nevro Announces FDA Approval of its 10 kHz High Frequency Spinal Cord Stimulation Therapy for Treatment of Chronic Pain Associated with Painful Diabetic Neuropathy (PDN)

HFX™ for PDN Now the Only Spinal Cord Stimulation System Approved by FDA to Treat PDN¹ Company Will Immediately Initiate Commercial Launch Activities in the U.S. Company Announces Preliminary, Unaudited Second Quarter 2021 Revenue of Approximate... Devices, Neurology, FDA, Product Launch Nevro Corp, Senza , diabetic neuropathy, spinal cord stimulation
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news